ArticleInfection and drug resistance2020
The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 61 citations in OpenAlex.
- Development and in vitro evaluation of teicoplanin PEGylated (TEC-PEGylated) niosomes for antimicrobial and anti-biofilm activity against vancomycin-intermediate Staphylococcus aureus (VISA).BMC biotechnology · 2026Article
- Sustainable Ag-Cu bimetallic nanozymes derived from Juglans regia husk exhibit multifunctional catalytic, antimicrobial, and antioxidant activities.Scientific reports · 2026Article
- Antibacterial activity of crocin-loaded niosomes against foodborne pathogens isolated from cream pastries.BMC microbiology · 2026Article
- Preparation and Characterization of Niosomes Containing Cationic Antimicrobial Peptides WSKK11 and WSRR11.ACS omega · 2026Article
- Surfactant-Engineered Niosomal Antibiotic Systems for Biofilm-Associated Infections: Design Principles and Translational Perspectives.International journal of nanomedicine · 2026Review
- Mucosomes as next-generation drug carriers for treating mucus-resident bacterial infections and biofilms.Scientific reports · 2025Article
- Study of Class 1, 2, and 3 Integrons, Antibiotic Resistance Patterns, and Biofilm Formation in ClinicalPathogens (Basel, Switzerland) · 2025Article
- Formulation and Characterization of Teicoplanin Niosomal Gel for Healing Chronic Wounds Infected with Methicillin-ResistantGels (Basel, Switzerland) · 2025Article
- Article
- Transdermal Delivery System of Doxycycline-Loaded Niosomal Gels: Toward Enhancing Doxycycline Stability.ACS omega · 2024Article
- Antibacterial and antibiofilm potentials of vancomycin-loaded niosomal drug delivery system against methicillin-resistant Staphylococcus aureus (MRSA) infections.BMC biotechnology · 2024Article
- Antibacterial and antibiofilm activities of zingerone and niosomal zingerone against methicillin-resistantIranian journal of microbiology · 2024Article
- Fabrication and antimicrobial properties of novel meropenem-honey encapsulated chitosan nanoparticles against multiresistant and biofilm-forming Staphylococcus aureus as a new antimicrobial agent.Veterinary medicine and science · 2024Article
- Article
- Article
- Larvicidal potential, antimicrobial properties and molecular docking analysis of Egyptian Mint (Mentha rotundifolia) against Culex pipiens L. (Diptera: Culicidae) and Midgut-borne Staphylococcus aureus.Scientific reports · 2024Article
- Article
- Regulation ofPharmaceutics · 2023Review
- Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.BioMed research international · 2023Review
- Niosomes-loaded selenium nanoparticles as a new approach for enhanced antibacterial, anti-biofilm, and anticancer activities.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe threat of
methodsThe antimicrobial susceptibility of clinical
resultsMost of the isolates were methicillin- (47/59) and ciprofloxacin-resistant (45/59). All except two isolates were capable of biofilm production. Niosomal preparation I reduced ciprofloxacin MIC by twofold in four isolates, whereas preparation II reduced ciprofloxacin MIC of most isolates by 8- to 32-fold, with three isolates that became ciprofloxacin-susceptible. Non-synonymous mutations were detected in isolates that maintained phenotypic ciprofloxacin resistance against ciprofloxacin-loaded niosomal preparation II. Ciprofloxacin-loaded niosomes reduced the minimum biofilm inhibitory concentration and the minimum biofilm eradication concentration in 58% and 62% of the tested isolates, respectively.
conclusionCiprofloxacin-loaded niosomes can restore ciprofloxacin activity against resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.